TY - JOUR
T1 - Characterization of Severe Asthma Worldwide
T2 - Data From the International Severe Asthma Registry
AU - Wang, Eileen
AU - Wechsler, Michael E.
AU - Tran, Trung N.
AU - Heaney, Liam G.
AU - Jones, Rupert C.
AU - Menzies-Gow, Andrew N.
AU - Busby, John
AU - Jackson, David J.
AU - Pfeffer, Paul E.
AU - Rhee, Chin Kook
AU - Cho, You Sook
AU - Canonica, G. Walter
AU - Heffler, Enrico
AU - Gibson, Peter G.
AU - Hew, Mark
AU - Peters, Matthew
AU - Harvey, Erin S.
AU - Alacqua, Marianna
AU - Zangrilli, James
AU - Bulathsinhala, Lakmini
AU - Carter, Victoria A.
AU - Chaudhry, Isha
AU - Eleangovan, Neva
AU - Hosseini, Naeimeh
AU - Murray, Ruth B.
AU - Price, David B.
PY - 2020/4
Y1 - 2020/4
N2 - Background: Clinical characteristics of the international population with severe asthma are unknown. Intercountry comparisons are hindered by variable data collection within regional and national severe asthma registries. We aimed to describe demographic and clinical characteristics of patients treated in severe asthma services in the United States, Europe, and the Asia-Pacific region. Methods: The International Severe Asthma Registry retrospectively and prospectively collected data in patients with severe asthma (≥ 18 years old), receiving Global Initiative for Asthma (GINA) Step 5 treatment or with severe asthma remaining uncontrolled at GINA Step 4. Baseline demographic and clinical data were collected from the United States, United Kingdom, South Korea, Italy, and the Severe Asthma Web-based Database registry (including Australia, Singapore, and New Zealand) from December 2014 to December 2017. Results: We included 4,990 patients. Mean (SD) age was 55.0 (15.9) years, and mean (SD) age at asthma onset was 30.7 (17.7) years. Patients were predominantly female (59.3%) and white (72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA Step 5; and 57.2% had poorly controlled disease. A total of 51.1% of patients were receiving regular intermittent oral corticosteroids, and 25.4% were receiving biologics (72.6% for those at GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7) per year. Intercountry variation was observed in clinical characteristics, prescribed treatments, and biomarker profiles. Conclusions: Using a common data set and definitions, this study describes severe asthma characteristics of a large patient cohort included in multiple severe asthma registries and identifies country differences. Whether these are related to underlying epidemiological factors, environmental factors, phenotypes, asthma management systems, treatment access, and/or cultural factors requires further study.
AB - Background: Clinical characteristics of the international population with severe asthma are unknown. Intercountry comparisons are hindered by variable data collection within regional and national severe asthma registries. We aimed to describe demographic and clinical characteristics of patients treated in severe asthma services in the United States, Europe, and the Asia-Pacific region. Methods: The International Severe Asthma Registry retrospectively and prospectively collected data in patients with severe asthma (≥ 18 years old), receiving Global Initiative for Asthma (GINA) Step 5 treatment or with severe asthma remaining uncontrolled at GINA Step 4. Baseline demographic and clinical data were collected from the United States, United Kingdom, South Korea, Italy, and the Severe Asthma Web-based Database registry (including Australia, Singapore, and New Zealand) from December 2014 to December 2017. Results: We included 4,990 patients. Mean (SD) age was 55.0 (15.9) years, and mean (SD) age at asthma onset was 30.7 (17.7) years. Patients were predominantly female (59.3%) and white (72.6%), had never smoked (60.5%), and were overweight or obese (70.4%); 34.9% were at GINA Step 5; and 57.2% had poorly controlled disease. A total of 51.1% of patients were receiving regular intermittent oral corticosteroids, and 25.4% were receiving biologics (72.6% for those at GINA Step 5). Mean (SD) exacerbation rate was 1.7 (2.7) per year. Intercountry variation was observed in clinical characteristics, prescribed treatments, and biomarker profiles. Conclusions: Using a common data set and definitions, this study describes severe asthma characteristics of a large patient cohort included in multiple severe asthma registries and identifies country differences. Whether these are related to underlying epidemiological factors, environmental factors, phenotypes, asthma management systems, treatment access, and/or cultural factors requires further study.
KW - biologics
KW - comorbidity
KW - eosinophils
KW - FENO
KW - IgE
UR - http://www.scopus.com/inward/record.url?scp=85081611905&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2019.10.053
DO - 10.1016/j.chest.2019.10.053
M3 - Article
C2 - 31785254
AN - SCOPUS:85081611905
SN - 0012-3692
VL - 157
SP - 790
EP - 804
JO - Chest
JF - Chest
IS - 4
ER -